Functional assessment of MeCP2 in Rett syndrome and cancers of breast, colon, and prostate.
Ever since the first report that mutations in methyl-CpG-binding protein 2 (MeCP2) causes Rett syndrome (RTT), a severe neurological disorder in females world-wide, there has been a keen interest to gain a comprehensive understanding of this protein. While the classical model associated with MeCP2 function suggests its role in gene suppression via recruitment of co-repressor complexes and histone deacetylases to methylated CpG-sites, recent discoveries have brought to light its role in transcription activation, modulation of RNA splicing, and chromatin compaction. Various post-translational modifications (PTMs) of MeCP2 further increase its functional versatility. Involvement of MeCP2 in pathologies other than RTT, such as tumorigenesis however, remains poorly explored and understood. This review provides a survey of the literature implicating MeCP2 in breast, colon and prostate cancer.
Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, 3601 4th Street, Lubbock, TX 79430, USA.|Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, 3601 4th Street, Lubbock, TX 79430, USA.
Somnath
S
Pandey
Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, 3601 4th Street, Lubbock, TX 79430, USA.|Immunology and Molecular Microbiology, Texas Tech University Health Sciences Center, 3601 4th Street, Lubbock, TX 79430, USA.
Kevin
K
Pruitt
D001943:Breast Neoplasms / Q000503:physiopathology*; D003110:Colonic Neoplasms / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008297:Male; D051783:Methyl-CpG-Binding Protein 2 / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000503:physiopathology*; D015518:Rett Syndrome / Q000503:physiopathology*
C497392:MECP2 protein, human; D051783:Methyl-CpG-Binding Protein 2
MeCP2; Rett; breast cancer; cancer de la prostate; cancer du côlon; cancer du sein; colon cancer; prostate cancer